What Wall Street and the Pros don't want you to know:
Great point: If Reduce-It study results turn out to be significant early(2014 or 2015 like JUPITER trials for Crestor)--then Sales estimates could be 6 billion$ per year.
Stock price under that assumption could push the price to 80$/share.
Many people are hung on--Launch by Amarin. They are looking for QUICK PROFIT.
Remember Warner Lambert(owner of Lipitor) did not get any BUYOUT in 1996 or 1997 or 1998. In 1998,it was obvious that LIPITOR is a blockbuster with 45% market share in 1999.Marketshare chart is unbelievable. It was only when WYETH(Amer.Home Products) who finalized a deal with WL in 1999. Then Pfizer WOKE up and bid 82 bil.$--LEGAL fights began and Pfizer ended paying Wyeth (AHP) 1,8 billion$ BREAKUP fees and 90 bil.$ for Lipitor(WL).
WL stock was so so in 1996--but when Lipitor was launched,it started to shoot up,going from 45-54 $ in first quarter 1996 to 108-152$/share in 4th qtr.1997.
Even then Pfizer did not make an offer in 1997--when all the data was in their hand-as they were marketing partner for Lipitor.
PLEASE look at PAUL Huff's resume--He was with Reliant from Feb.2004 to beginning of 2008 as VP-marketing/business develop. Under his leadership--Sales grew from Zero in 2005 to 500mil.$ in 2007 ( GSK press release says first 9 months sales for 2007 were 341mil.$ growing at 62% from previous year 9months.
Yes--Stock price may not go up a lot in 2012,but it will go up in 2014 to above 30$/share. and possibly 80$/share in 2015 or 2016.
I am dead set in my opinion...until I see facts that convince me otherwise!
I have been reading your posts about the officers. "Been there, done that" seems to sum it up as far as a Vescepa roll-out is concerned. If it is at all possible, my blood pressure and stomach acid production would appreciate a nice BO with the CVRs that contrydoc has been posting about. I am confident in the AMRN end game but would like to take some downside risk out in case there is a big snafu.